Augmentation Therapy for α₁ Antitrypsin Deficiency: A Meta-Analysis

REFERENCES

• Wewers M D, Casolaro M A, Sellers S E, Swayze S C, Mcphaul K M, Wittes J T, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055–1062
   PubMed Web of Science ®Google Scholar
• Schwaiblmair M, Vogelmeier C, Fruhmann G. Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency–three-year follow-up. Respiration 1997; 64(1)10–15
   PubMed Web of Science ®Google Scholar
• Wencker M, Denker J, Konietzko N. Serial measurements of FEV1 over 12 years in a patient with alpha-1-protease inhibitor deficiency: Influence of augmentation therapy and infections. Respiration 1994; 61(4)195–198
   PubMed Web of Science ®Google Scholar
• Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, et al. Does alpha12-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency?. Eur Respir J 1997; 10: 2260–2263
   PubMed Web of Science ®Google Scholar
• Vreim C E, Wu M, Crystal R G, Buist A S, Burrows B, Cohen A B, et al. Survival and FEV1 decline in individuals with severe deficiency of A1-antitrypsin. Am J Respir Crit Care Med 1998; 158(1)49–59
   PubMed Web of Science ®Google Scholar
• Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche arbeitsgemeinschaft zur therapie von lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998; 11(2)428–433
   PubMed Web of Science ®Google Scholar
• Dirksen A, Dijkman J H, Madsen F, Stoel B, Hutchison D CS, Ulrik C S, et al. A randomized clinical trial of A1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160(5)1468–1472
   PubMed Web of Science ®Google Scholar
• Wencker M, Fuhrmann B, Banik N, Konietzko N, Wissenschaftliche A. Longitudinal follow-up of patients with A1-protease inhibitor deficiency before and during therapy with IV A1-protease inhibitor. Chest 2001; 119(3)737–744
   PubMed Web of Science ®Google Scholar
• Stockley R A, Bayley D L, Unsal I, Dowson L J. The effect of augmentation therapy on bronchial inflammation in A1-antitrypsin deficiency. Am J Respir Crit Care Med 2002; 165(11)1494–1498
   PubMed Web of Science ®Google Scholar
• Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: A new hypothesis with supporting data. Chest 2000; 118(5)1480–1485
   PubMed Web of Science ®Google Scholar
• Gottlieb D J, Luisetti M, Stone P J, Allegra L, Cantey-Kiser J M, Grassi C, et al. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The american-italian AATD study group. Am J Respir Crit Care Med 2000; 162(6)2069–2072
   PubMed Web of Science ®Google Scholar
• Stoller J K. Augmentation therapy for severe a1-antitrypsin deficiency: Is the jury still out on a trial?. Thorax 1998; 53(12)1007–1009
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, et al. Canadian thoracic society recommendations for management of chronic obstructive pulmonary disease–2003. Can Respir J 2003; 10(Suppl A)11A–65A
   PubMedGoogle Scholar
• Abboud R T, Ford G T, Chapman K R. Alpha1-antitrypsin deficiency: A position statement of the canadian thoracic society. Can Respir J 2001; 8(2)81–88
   PubMedGoogle Scholar
• Egger M, Smith G D. Bias in location and selection of studies. BMJ 1998; 316(7124)61–66
   PubMed Web of Science ®Google Scholar
• Egger M, Davey S G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109)629–634
   PubMed Web of Science ®Google Scholar
• Schulz K F, Chalmers I, Hayes R J, Altman D G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273(5)408–412
   PubMed Web of Science ®Google Scholar
• Stram D O. Meta-analysis of published data using a linear mixed-effects model. Biometrics 1996; 52(2)536–544
   PubMed Web of Science ®Google Scholar
• Shea S, Dumouchel W, Bahamonde L. A Meta-analysis of 16 randomized controlled trials to evaluate computer-based clinical reminder systems for preventive care in the ambulatory setting. J Am Med Inform Assoc 1996; 3(6)399–409
   PubMed Web of Science ®Google Scholar
• Lau J, Ioannidis J P, Schmid C H. Summing up evidence: One answer is not always enough. Lancet 1998; 351(9096)123–127
   PubMed Web of Science ®Google Scholar
• Sharp S, Sterne J. Meta-analysis. 1997; 100–106, Stata Tech Bull STB-38
   Google Scholar
• Steichen T J, Egger M, Sterne J. Tests for publication bias in meta-analysis. 1998; 84–85, Stata Tech Bull STB-44
   Google Scholar
• Chapman K R, Bradi A C, Paterson D, Navickis R J, Wilkes M M. Slower lung function decline during augmentation therapy in patients with alpha1-antitrypsin deficiency (A1ATD): Results from the canadian AIR registry. Proc.Am.Thorac.Soc. 2005; 2: A808
   Google Scholar
• Buist A S, Burrows B, Eriksson S, Mittman C, Wu M. The natural history of air-flow obstruction in piz emphysema. Report of an NHLBI workshop. Am Rev Respir Dis 1983; 127(2)S43–S45
   PubMed Web of Science ®Google Scholar
• Brantly M L, Paul L D, Miller B H, Falk R T, Wu M, Crystal R G. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988; 138(2)327–336
   PubMed Web of Science ®Google Scholar
• Hubbard R C, Sellers S, Czerski D, Stephens L, Crystal R G. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 1988; 260: 1259–1264
   PubMed Web of Science ®Google Scholar
• Konietzko N, Becker M, Schmidt E W, Rasche B, Ulmer W T, Ferlinz R, et al. [Substitution therapy with alpha-1-Pi in patients with alpha-1-Pi deficiency and progressive pulmonary edema]. Dtsch Med Wochenschr 1988; 113(10)369–373
   PubMed Web of Science ®Google Scholar
• Schmidt E W, Rasche B, Ulmer W T, Konietzko N, Becker M, Fallise J P, et al. Replacement therapy for alpha-1-protease inhibitor deficiency in piz subjects with chronic obstructive lung disease. Am J Med 1988; 84(6A)63–69
   PubMed Web of Science ®Google Scholar
• Ulmer W T, Schmidt E W, Rasche B. Long term effect on lung function of alpha 1-protease inhibitor substitution therapy in COPD patients with Pi ZZ phenotype. Eur Respir J Suppl 1990; 9: 21s–22s
   PubMedGoogle Scholar
• Miravitlles M, Vidal R, Torrella M, Bofill J M, Cotrina M, De G J. [Evaluation of replacement therapy in emphysema caused by alpha 1-antitrypsin deficiency]. Arch Bronconeumol 1994; 30(10)479–484
   PubMedGoogle Scholar
• Stone P J, Morris T A, III, Franzblau C, Snider G L. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1-antitrypsin-deficient humans. Respiration 1995; 62(2)76–79
   PubMed Web of Science ®Google Scholar
• Barker A F, Iwata-Morgan I, Oveson L, Roussel R. Pharmacokinetic study of A1-antitrypsin infusion in A1-antitrypsin deficiency. Chest 1997; 112(3)607–613
   PubMed Web of Science ®Google Scholar
• Stoller J K, Rouhani F, Brantly M, Shahin S, Dweik R A, Stocks J A, et al. Biochemical efficacy and safety of a new pooled human plasma a1-antitrypsin, respitin. Chest 2002; 122(1)66–74
   PubMed Web of Science ®Google Scholar
• Kjus T, Lutzow-Holm C, Christensen O B. Treatment of panniculitis associated with alpha-1-antitrypsin deficiency with alpha-1-protease inhibitor. Acta Derm Venereol 2003; 83(6)462–463
   PubMed Web of Science ®Google Scholar
• Piitulainen E, Bernspang E, Bjorkman S, Berntorp E. Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin. Eur J Clin Pharmacol 2003; 59(2)151–156
   PubMed Web of Science ®Google Scholar
• Silva G E, Sherrill D L, Guerra S, Barbee R A. A longitudinal study of alpha1-antitrypsin phenotypes and decline in FEV1 in a community population. Chest 2003; 123(5)1435–1440
   PubMed Web of Science ®Google Scholar
• Graf H J, Drenker J, Konietzko N. Lung function study of the german multicenter group (WATL) in Á1-PI deficient patients with severe lung emphysema before and under substitution therapy. Am Rev Respir Dis 1991; 143(Suppl.)A672
   Google Scholar
• Barker A F, Siemsen F, Pasley D, D'Silva R, Buist A S. Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration. Chest 1994; 105(5)1406–1410
   PubMed Web of Science ®Google Scholar
• Seersholm N, Kok-Jensen A, Dirksen A. Decline in FEV1 among patients with severe hereditary a1-antitrypsin deficiency type Piz. Am J Respir Crit Care Med 1995; 152: 1922–1925, (6 PT 1)
   PubMed Web of Science ®Google Scholar
• Dirksen A, Friis M, Olesen K P, Skovgaard L T, Sorensen K. Progress of emphysema in severe a1-antitrypsin deficiency as assessed by annual CT. Acta Radiol 1997; 38(5)826–832
   PubMed Web of Science ®Google Scholar
• Mcelvaney N G, Stoller J K, Buist A S, Prakash U BS, Brantly M L, Schluchter M D, et al. Baseline characteristics of enrollees in the national heart, lung and blood institute registry of a1-antitrypsin deficiency. Chest 1997; 111(2)394–403
   PubMed Web of Science ®Google Scholar
• Dirksen A, Holstein-Rathlou N H, Madsen F, Skovgaard L T, Ulrik C S, Heckscher T, et al. Long-range correlations of serial FEV1 measurements in emphysematous patients and normal subjects. J Appl Physiol 1998; 85(1)259–265
   PubMed Web of Science ®Google Scholar
• Dowson L J, Guest P J, Stockley R A. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001; 164: 1805–1809, (10 Pt 1)
   PubMed Web of Science ®Google Scholar
• Stoller J K, Fallat R, Schluchter M D, O'Brien R G, Connor J T, Gross N, et al. Augmentation therapy with alpha1-antitrypsin: Patterns of use and adverse events. Chest 2003; 123(5)1425–1434
   PubMed Web of Science ®Google Scholar
• Luisetti M, Miravitlles M, Stockley R A. Alpha1-antitrypsin deficiency: A report from the 2nd meeting of the alpha one international registry, Rapallo (Genoa, Italy), 2001. Eur Respir J 2002; 20(4)1050–1056
   PubMedGoogle Scholar
• Bailar J C, III. The promise and problems of meta-analysis. N Engl J Med 1997; 337(8)559–561
   PubMed Web of Science ®Google Scholar
• Burrows B. A clinical trial of efficacy of antiproteolytic therapy: Can it be done?. Am Rev Respir Dis 1983; 127(2)S42–S43
   PubMed Web of Science ®Google Scholar
• Suissa S. Lung function decline in COPD trials: Bias from regression to the mean. Eur Respir J 2008; 32(4)829–831
   PubMed Web of Science ®Google Scholar
• Rennard S I. Minimal clinically important difference, clinical perspective: An opinion. COPD 2005; 2(1)51–55
   PubMedGoogle Scholar
• Decramer M, Celli B, Tashkin D P, Pauwels R A, Burkhart D, Cassino C, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: The UPLIFT trial. COPD 2004; 1(2)303–312
   PubMedGoogle Scholar
• Celli B, Ferguson G T, Anderson J A, Jenkins C R, Jones P W, Vestbo J, et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study. Proc Am Thorac Soc 2006; 175: A763
   Google Scholar
• Stroup D F, Berlin J A, Morton S C, Olkin I, Williamson G D, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283(15)2008–2012
   PubMed Web of Science ®Google Scholar
• Hutchison D C, Cooper D. Alpha-1-antitrypsin deficiency: Smoking, decline in lung function and implications for therapeutic trials. Respir Med 2002; 96(11)872–880
   PubMed Web of Science ®Google Scholar
• Benson K, Hartz A J. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342(25)1878–1886
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz R I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342(25)1887–1892
   PubMed Web of Science ®Google Scholar
• Ioannidis J P, Haidich A B, Pappa M, Pantazis N, Kokori S I, Tektonidou M G, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286(7)821–830
   PubMed Web of Science ®Google Scholar
• Schluchter M D, Stoller J K, Barker A F, Buist A S, Crystal R G, Donohue J F, et al. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The alpha 1-antitrypsin deficiency registry study group. Am J Respir Crit Care Med 2000; 161: 796–801, (3 Pt 1)
   PubMed Web of Science ®Google Scholar
• Jelenko C, III, Williams J B, Wheeler M L, Callaway B D, Fackler V K, Albers C A, et al. Studies in shock and resuscitation, I: Use of a hypertonic, albumin-containing, fluid demand regimen (HALFD) in resuscitation. Crit Care Med 1979; 7(4)157–167
   PubMed Web of Science ®Google Scholar
• Rackow E C, Falk J L, Fein I A, Siegel J S, Packman M I, Haupt M T, et al. Fluid resuscitation in circulatory shock: A comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 1983; 11(11)839–850
   PubMed Web of Science ®Google Scholar
• Metildi L A, Shackford S R, Virgilio R W, Peters R M. Crystalloid versus colloid in fluid resuscitation of patients with severe pulmonary insufficiency. Surg Gynecol Obstet 1984; 158(3)207–212
   PubMedGoogle Scholar
• Hoeft A, Korb H, Mehlhorn U, Stephan H, Sonntag H. Priming of cardiopulmonary bypass with human albumin or ringer lactate: Effect on colloid osmotic pressure and extravascular lung water. Br J Anaesth 1991; 66(1)73–80
   PubMed Web of Science ®Google Scholar
• Martin G S, Mangialardi R J, Wheeler A P, Dupont W D, Morris J A, Bernard G R. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med 2002; 30(10)2175–2182
   PubMed Web of Science ®Google Scholar
• Soy D, De La R C, Lara B, Esquinas C, Torres A, Miravitlles M. Alpha-1-antitrypsin deficiency: Optimal therapeutic regimen based on population pharmacokinetics. Thorax 2006; 61(12)1059–1064
   PubMed Web of Science ®Google Scholar
• Hutchison D CS, Hughes M D. Alpha-1-antitrypsin replacement therapy: Will its efficacy ever be proved?. Eur Respir J 1997; 10: 2191–2193
   PubMed Web of Science ®Google Scholar
• Lelorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337(8)536–542
   PubMed Web of Science ®Google Scholar